AST 915 in patients with essential tremor.

Trial Profile

AST 915 in patients with essential tremor.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2010

At a glance

  • Drugs AST 915 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2010 Results are expected to be presented at the 15th International Congress of Parkinson's Disease and Movement Disorders, according to a Manhattan Pharmaceuticals media release.
    • 16 Dec 2010 Primary endpoint 'Clinical-response' has not been met, according to a Manhattan Pharmaceuticals media release.
    • 16 Dec 2010 Interim results reported in a Manhattan Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top